These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23953051)

  • 1. [Clinical cfficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hypertension].
    Maksimov ML; Malykhina AI
    Kardiologiia; 2013; 53(6):85-90. PubMed ID: 23953051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Lercanidipine, a third generation calcium antagonist. Which advantages?].
    Meier P; Burnier M
    Rev Med Suisse; 2006 Sep; 2(78):2047-50, 2052-3. PubMed ID: 17019840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical efficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hypertension and metabolic disorders (review)].
    Tabidze GA; Gezeli TD; Tsibadze TA; Dolidze NM
    Georgian Med News; 2015 Feb; (239):51-6. PubMed ID: 25802450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M; Pruijm M; Wuerzner G
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lercanidipine in the treatment of arterial hypertension].
    Minushkina LO; Iosava IK
    Kardiologiia; 2012; 52(12):70-4. PubMed ID: 23237444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.
    Pruijm MT; Maillard MP; Burnier M
    Vasc Health Risk Manag; 2008; 4(6):1159-66. PubMed ID: 19337529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of lercanidipine in the general practice setting].
    Robles NR; Canelada JA; Iglesias M; Angulo E; López Acedo A; Díaz Olea E; Cidoncha F; Guerras M; Fuentes J; Garrido J; Lapie J; Peña J; Aguilar A; Hidalgo P
    An Med Interna; 2003 Jun; 20(6):282-6. PubMed ID: 12848597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug information about lercanidipine. A new dihydropyridine calcium antagonist for the treatment of arterial hypertension].
    Christensen KL
    Ugeskr Laeger; 2005 Jan; 167(2):153-5. PubMed ID: 15697124
    [No Abstract]   [Full Text] [Related]  

  • 9. Some similarities and differences between verapamil and the dihydropyridines.
    Antonios TF; MacGregor GA
    J Hypertens Suppl; 1998 Jan; 16(1):S31-4. PubMed ID: 9534094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of psychosomatic symptomatology in hypertensive patients treated with lercanidipine (LERCAPSICO study)].
    Abellán Alemán J; Martínez García JF; Merino Sánchez J; Gil Guillén V; Latorre Hernández J; Fernández Montero F; Navarro Lima A;
    An Med Interna; 2003 Jun; 20(6):287-91. PubMed ID: 12848598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium channel blockers: differences between subclasses.
    Frishman WH
    Am J Cardiovasc Drugs; 2007; 7 Suppl 1():17-23. PubMed ID: 19845073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers.
    Makarounas-Kirchmann K; Glover-Koudounas S; Ferrari P
    Clin Ther; 2009 Aug; 31(8):1652-63. PubMed ID: 19808126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of a third generation calcium antagonist in the management of hypertension.
    Epstein M
    Drugs; 1999; 57 Suppl 1():1-10. PubMed ID: 10529076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension.
    Ogura C; Ono K; Miyamoto S; Ikai A; Mitani S; Sugimoto N; Tanaka S; Fujita M
    Blood Press; 2012 Dec; 21(6):367-71. PubMed ID: 22747420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lercanidipine in hypertension.
    Borghi C
    Vasc Health Risk Manag; 2005; 1(3):173-82. PubMed ID: 17319103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension, possible vascular protection and lercanidipine.
    Ram CV
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):783-8. PubMed ID: 17173495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Third generation of calcium antagonists: focus on lacidipine].
    Sidorenko BA; Stetsenko TM; Preobrazhenskiĭ DV; Savchenko MV; Soplevenko AV; Shabaeva EN
    Kardiologiia; 2002; 42(12):81-90. PubMed ID: 12494025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lercanidipine in the treatment of hypertension.
    Beckey C; Lundy A; Lutfi N
    Ann Pharmacother; 2007 Mar; 41(3):465-73. PubMed ID: 17341540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydropyridine calcium channel blockers and renal disease.
    Robles NR; Fici F; Grassi G
    Hypertens Res; 2017 Jan; 40(1):21-28. PubMed ID: 27412800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A rational approach to the treatment of arterial hypertension in patients with high cardiovascular risk and metabolic disorders].
    Mamedov MN; Kovrigina MN; Toguzova ZA
    Kardiologiia; 2013; 53(2):85-90. PubMed ID: 23548396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.